Recent developments in pharmacophore-based modeling of Ca 2+/ Calmodulin-dependent protein kinase II delta (CaMkIIδ) inhibitors for heart failure therapy

Key Result

Pharmacophore-driven modeling and AI integration can lead to the development of selective CaMKIIδ inhibitors that are potent and clinically viable for heart failure therapy.

Key Points

• To enhance pharmacophore modeling of CaMKIIδ inhibitors for effective heart failure therapy.
• Utilized pharmacophore-driven approaches for modeling.
• Integrated AI and deep learning technologies.
• Developed isoform-aware selectivity filters.
• Focused on state- and post-translational modification (PTM)-specific targeting.
• Implemented experimental validation for inhibitor efficacy.
• Improved selectivity against CaMKII isoforms.
• Identification of clinically viable inhibitors for heart failure.
• Enhanced understanding of benchmarking and translation processes.